share_log

Needham Maintains Buy on Revolution Medicines, Raises Price Target to $62

Needham Maintains Buy on Revolution Medicines, Raises Price Target to $62

Needham維持對revolution medicines的買入評級,將目標股價上調至62美元。
Benzinga ·  07/16 07:28

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $46 to $62.

Needham分析師Ami Fadia維持了Revolution Medicines (NASDAQ:RVMD)的買入評級,將價格目標從46美元上調至62美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論